Freeze-Dried Product Development Workflow | Why “Dry” Protects Bioactivity —Hyasen Lyophilization Services: Safeguarding Bioactive Materials
In molecular diagnostics, biopharmaceuticals, and research reagents, the stability of bioactive substances such as enzymes, antibodies, antigens, and nucleic acids directly determines product quality and performance. Vacuum freeze-drying (lyophilization) is a core technology for achieving long-term stability and convenient storage and transport of bioactive materials. Leveraging deep expertise in molecular biology reagents, Hyasen Biotech offers professional lyophilization services, enabling clients to upgrade products from formulation development to commercial-scale production, ensuring bioactivity is locked, preserved, and reliably delivered.
Lyophilization is essentially sublimation dehydration under low temperature and vacuum—samples are first frozen, then ice sublimates directly into vapor in a vacuum, completely avoiding high temperatures and liquid water, thereby protecting bioactivity at the source.
- Accelerates degradation: Liquid water promotes hydrolysis, oxidation, and aggregation of proteins and enzymes, leading to rapid activity loss.
- Microbial growth: Water content >5% encourages bacteria and mold contamination, shortening shelf life.
- Freeze-thaw damage: Repeated freeze-thaw cycles disrupt molecular structures, reducing batch consistency.
Continuous -40°C to -20°C processing perfectly preserves the native structure and activity of sensitive materials such as enzymes, antibodies, and vaccines.
Water content precisely controlled at 1%-3%, extending shelf life (stable at room temperature for 1–2 years, replacing -20°C cold chain).
Sublimated ice forms a honeycomb-like microstructure; add water for instant dissolution, no vortexing required.
Room temperature storage and transport reduce dry ice and freezer costs, especially suitable for overseas and decentralized sites.
Lyophilization is a systematic engineering process; formulation, process, equipment, and quality control are all essential. Hyasen has established a standardized and reproducible workflow, covering lab-scale → pilot-scale → commercial production, ensuring each batch retains stable activity and uniform morphology.
Direct lyophilization of bioactive materials may lead to inactivation; protectants (trehalose, mannitol, sucrose, etc.) act as “activity guardians.”
- Test different protectant combinations and concentrations.
- Evaluate the impact on bioactivity, thermal stability, and cake morphology.
- Optimize buffer systems (pH, ionic strength).
- Pre-freezing: Gradient cooling from -40°C to -20°C.
- Primary drying: Vacuum 10–30 Pa, temperature gradually raised to 0°C.
- Secondary drying: Temperature raised to 20–30°C, moisture to 1%-3%.
- Test small batches for activity recovery and reconstitution time.
- Accelerated stability tests (37°C/7 days, 25°C/30 days).
- Scale up to pilot batches to verify scalability.
- Adapt to automated filling, lyophilization, and capping equipment.
- Production in Class 10,000 cleanrooms with full aseptic control.
- Each batch tested for activity, moisture, appearance, and microbial limits.
- Deep technical expertise, multi-product compatibility: Specializes in molecular diagnostic reagent lyophilization (qPCR / isothermal amplification enzymes).
- Customized solutions, fast implementation: 2–4 weeks for lab-scale development, shortening time to market.
- Reliable quality assurance: Core enzyme raw materials are self-developed; batch-to-batch variation <5%.
- Cost reduction and efficiency: Room temperature storage and transport reduce logistics costs by 30%-50%.
- IVD molecular diagnostics: Freeze-dried PCR enzymes, reverse transcriptases, and isothermal amplification reagents.
- Research reagents: Freeze-dried enzymes and nucleic acids, convenient for laboratory storage.